iScience (Nov 2023)

Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache

  • Zihua Gong,
  • Chunxiao Yang,
  • Wei Dai,
  • Shuai Miao,
  • Yingyuan Liu,
  • Zhiyang Jiao,
  • Bozhi Li,
  • Wei Xie,
  • Wei Zhao,
  • Xun Han,
  • Shengyuan Yu,
  • Zhao Dong

Journal volume & issue
Vol. 26, no. 11
p. 108153

Abstract

Read online

Summary: Medication overuse headache (MOH) is a serious global condition. The interaction between headache attacks and medication overuse complicates the understanding of its pathophysiology. In this study, we developed a preclinical MOH model that incorporates these two key factors by overusing rizatriptan benzoate (RIZ, 4 mg/kg, i.g.) in a glyceryl trinitrate (GTN, 10 mg/kg, i.p.) induced chronic migraine mouse model. We observed that RIZ overuse aggravated GTN-induced cutaneous allodynia and caused a prolonged state of latent sensitization. We also detected a significant upregulation of Annexin-A1 (ANXA1), a protein mainly expressed in the microglia of the spinal trigeminal nucleus caudalis (SPVC), in GTN+RIZ mice. Intracerebroventricular injection of ANXA1-derived peptide Ac2-26 trifluoroacetic acid (TFA) (5 μg/mouse) inhibited bright light stress (BLS) induced acute allodynia via the formyl peptide receptor (FPR) in GTN+RIZ mice. These results suggest that ANXA1 may have an analgesic effect in triptan-associated MOH and could potentially serve as a therapeutic target.

Keywords